Sudeep Pharma IPO allotment goes live today with a strong GMP of 17–18 percent. Check expected listing price, business overview, financial performance, investor response and a clear listing-day profit booking strategy. Suitable for both short-term and long-term investors.
Sudeep Pharma IPO Allotment Live Today: GMP, Listing Strategy & Long-Term View Explained
Sudeep Pharma IPO allotment is going live shortly, and investors are already excited because the GMP (Grey Market Premium) is running strong at 17–18%. If you’re waiting for your allotment status, planning for listing-day profit booking, or wondering whether this IPO is worth holding long-term — this article covers everything you need.
Sudeep Pharma IPO Allotment & Listing Date
- Allotment Date: 26 November
- Listing Date: 28 November
- Less than 48 hours are left for the listing, and market sentiment is currently positive with Nifty near all-time highs.
You can also check live allotment status through the official link available on various IPO update channels.
Latest GMP (Grey Market Premium)
As of today, the GMP is ₹17–18%, indicating strong listing-day demand.
This hints that the stock may list around ₹690–₹700, even though the issue price is ₹593.
Based on recent trends (like Exicom IPO listing stronger than GMP), the listing may even surprise on the higher side.
About Sudeep Pharma: What the Company Does
Sudeep Pharma is not a small or new company.
It is a market leader, manufacturing essential mineral-based products such as:
- Zinc
- Iron
- Calcium
- Magnesium
- Omega-3 products
- Multivitamin and nutraceutical ingredients
These are used widely in the pharma and nutrition industry, where demand is rising rapidly.
Key company highlights
- Export presence in 100+ countries
- Founded in 1989 — over 35 years of operations
- Strong reputation in the global mineral-based pharma ingredients market
Financial Performance Review
Before listing, the company’s valuations and financials look like this:
Valuation
- Market Cap (pre-listing): ₹6,700 crore
- P/E Ratio: 48× (reasonable for pharma & nutraceuticals sector)
Profitability
- ROCE: 35%
- ROE: 32%
These are excellent, showing strong operational efficiency.
Growth
Last 12 months:
- Revenue growth: 9%
- Net profit growth: 4%
Not very impressive — but temporary.
5-year growth:
- Revenue CAGR: 32%
- Profit CAGR: 50%
This shows the company has delivered consistent long-term growth.
Anchor Investor Confidence
Sudeep Pharma received strong demand from top institutional investors:
- SBI
- ICICI
- Kotak
- Other major mutual funds & FIIs
QIB subscription crossed 200×, showing heavy long-term confidence.
Mutual funds investing at this scale indicates the company may perform well over the coming years.
Listing Day Strategy (High-Probability Plan)
Expected Listing Range
- Base expectation: ₹690–₹700
- Optimistic scenario: ₹725–₹750
- High momentum target: ₹825–₹900+ (if market sentiment is very strong)
Profit Booking Plan
If you get allotment:
Target 1: ₹750 → Book 40% quantity
Target 2: ₹825 → Book 30% quantity
Target 3: ₹900+ → Book remaining 30%
This helps lock profits while still allowing upside.
Should You Hold Sudeep Pharma for Long Term?
Yes — but only as a small portion of your portfolio.
Reason:
- Strong leadership in mineral-based ingredients
- Rising global demand for nutraceuticals
- Strong export footprint
- Large mutual funds invested
- Good financial track record
Suggested long-term allocation: 5–7% of portfolio.
If You Don’t Get Allotment: Fresh Buying Strategy
Fresh buying opportunity may come only if:
✔️ Stock lists below ₹650
(meaning less than 10% premium)
In that case:
- Stop-loss: 3–4%
- Target: 10–15% short-term bounce
Strong companies often recover quickly after weak listing.
Final Verdict
Sudeep Pharma IPO is fundamentally strong with:
✔ Strong GMP
✔ Heavy subscription
✔ Big institutional support
✔ Consistent long-term financial growth
✔ Huge demand in pharma & nutrition space
Short-term traders can follow listing strategy, and long-term investors may consider holding a small allocation.